WO2004018636A3 - Methods for modulating transcriptional activation using mint proteins - Google Patents
Methods for modulating transcriptional activation using mint proteins Download PDFInfo
- Publication number
- WO2004018636A3 WO2004018636A3 PCT/US2003/026436 US0326436W WO2004018636A3 WO 2004018636 A3 WO2004018636 A3 WO 2004018636A3 US 0326436 W US0326436 W US 0326436W WO 2004018636 A3 WO2004018636 A3 WO 2004018636A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mint
- transcriptional activation
- modulate
- proteins
- present
- Prior art date
Links
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 title abstract 7
- 101100513476 Mus musculus Spen gene Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 210000005220 cytoplasmic tail Anatomy 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 102100036514 Amyloid-beta A4 precursor protein-binding family A member 1 Human genes 0.000 abstract 1
- 101710093637 Amyloid-beta A4 precursor protein-binding family A member 1 Proteins 0.000 abstract 1
- 102100036441 Amyloid-beta A4 precursor protein-binding family A member 2 Human genes 0.000 abstract 1
- 101710093616 Amyloid-beta A4 precursor protein-binding family A member 2 Proteins 0.000 abstract 1
- 102100036440 Amyloid-beta A4 precursor protein-binding family A member 3 Human genes 0.000 abstract 1
- 101710093619 Amyloid-beta A4 precursor protein-binding family A member 3 Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000009510 drug design Methods 0.000 abstract 1
- 238000011813 knockout mouse model Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- High Energy & Nuclear Physics (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention is directed to isolated nucleic acids encoding Mint protein variants having enhanced abilities to modulate the transcriptional activation mediated by the cytoplasmic tail of the amyloid precursor protein (APP) relative to wild-type Mint proteins. The present invention is further directed toward purified Mint protein variants having enhanced abilities to modulate the transcriptional activation mediated by the cytoplasmic tail of APP relative to wild-type Mint proteins. The present invention also encompasses methods of modulating transcriptional activation and methods of identifying compounds that modulate transcriptional activation, and vectors, as well as transfected cells and kits useful for modulating transcriptional activation or for the identification of compounds that can modulate transcriptional activation. The present invention further encompasses transgenic knockout mice with little or no expression of Mint 1, Mint 2 or Mint 3 proteins. Such reagents may be useful as candidate therapeutics for Alzheimer's disease (AD), or as models for the rational design of drugs useful for the treatment of AD.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003260020A AU2003260020A1 (en) | 2002-08-23 | 2003-08-22 | Methods for modulating transcriptional activation using mint proteins |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/227,490 | 2002-08-23 | ||
| US10/227,490 US7081337B2 (en) | 2001-03-30 | 2002-08-23 | Methods for modulating transcriptional activation using mint proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004018636A2 WO2004018636A2 (en) | 2004-03-04 |
| WO2004018636A3 true WO2004018636A3 (en) | 2004-10-07 |
Family
ID=31946340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2003/026436 WO2004018636A2 (en) | 2002-08-23 | 2003-08-22 | Methods for modulating transcriptional activation using mint proteins |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US7081337B2 (en) |
| AU (1) | AU2003260020A1 (en) |
| WO (1) | WO2004018636A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0402106D0 (en) | 2004-01-30 | 2004-03-03 | Syngenta Participations Ag | Improved fertility restoration for ogura cytoplasmic male sterile brassica and method |
| WO2005119262A2 (en) * | 2004-05-27 | 2005-12-15 | Galapagos N.V. | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| US20060172964A1 (en) * | 2005-02-01 | 2006-08-03 | Tanzi Rudolph E | Methods for reducing amyloid beta levels |
| US9034299B2 (en) | 2007-08-03 | 2015-05-19 | Cornell University | ATF4 inhibitors and their use for neural protection, repair, regeneration, and plasticity |
| CN109586881B (en) * | 2017-09-29 | 2021-11-12 | 株式会社Kt | Method and apparatus for switching bandwidth parts in a new radio |
| WO2019179985A1 (en) * | 2018-03-19 | 2019-09-26 | University Of Copenhagen | Inhibitors of mint and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US34884A (en) * | 1862-04-08 | Improved fastener for lamp-chimneys | ||
| DE19856261C1 (en) | 1998-12-07 | 2000-03-30 | Hoechst Marion Roussel De Gmbh | Detection of gamma-secretase by detection of A-beta peptide useful for determining gamma-secretase activity and for identifying inhibitors |
-
2002
- 2002-08-23 US US10/227,490 patent/US7081337B2/en not_active Expired - Fee Related
-
2003
- 2003-08-22 WO PCT/US2003/026436 patent/WO2004018636A2/en not_active Application Discontinuation
- 2003-08-22 AU AU2003260020A patent/AU2003260020A1/en not_active Abandoned
-
2006
- 2006-06-05 US US11/447,182 patent/US7422856B2/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| BIEDERER ET AL: "Regulation of APP-dependent transcription complexes by Mint/X11s: Differential functions of Mint isoforms", THE JOURNAL OF NEUROSCIENCE, vol. 22, no. 17, 1 September 2002 (2002-09-01), pages 7340 - 7351, XP002978481 * |
| OKAMOTO ET AL: "Amyloid precursor protein associates independently and collaboratively with PTB and PDZ domains of mint on vesicles and at cell membrane", NEUROSCIENCE, vol. 104, no. 3, 2001, pages 653 - 665, XP002978480 * |
| SUDHOF ET AL: "Mint 3: A ubiquitous mint isoform that does not bind to munc18-1 or -2", EUROPEAN JOURNAL OF CELL BIOLOGY, vol. 77, November 1998 (1998-11-01), pages 161 - 165, XP002978660 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20070037188A1 (en) | 2007-02-15 |
| WO2004018636A2 (en) | 2004-03-04 |
| US7081337B2 (en) | 2006-07-25 |
| US20030036169A1 (en) | 2003-02-20 |
| AU2003260020A8 (en) | 2004-03-11 |
| US7422856B2 (en) | 2008-09-09 |
| AU2003260020A1 (en) | 2004-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0300369A2 (en) | Multivalent antibodies and uses therefor | |
| WO2002031134A3 (en) | Novel serine protease genes related to dppiv | |
| WO1998031818A3 (en) | Tace-like and matrilysin-like polypeptides | |
| DK1641818T3 (en) | Polypeptides that have binding affinity for HER2 | |
| WO2001055343A8 (en) | Nucleic acids, proteins, and antibodies | |
| WO2007050705A3 (en) | Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof | |
| ATE474926T1 (en) | USE OF CLYA HEMOLYSIN FOR EXCRETION OF FUSION PROTEIN | |
| WO2004018636A3 (en) | Methods for modulating transcriptional activation using mint proteins | |
| WO2000043493A8 (en) | Metalloproteinase adam 22 | |
| EP1044605A4 (en) | Gene mutant animals | |
| WO2004074448A3 (en) | mTOR KINASE-ASSOCIATED PROTEINS | |
| DE60332579D1 (en) | Process for immobilizing polypeptides via the carboxyl group of the C-terminus | |
| BR0113099A (en) | Schizophrenia-related gene and protein | |
| WO2004042083A3 (en) | Nucleic acid ligands and uses therefor | |
| SE0301987D0 (en) | New polypeptide | |
| WO1998024887A3 (en) | Parasitic nematode transglutaminase proteins, nucleic acid molecules, and uses thereof | |
| HUP0002234A2 (en) | Vascular adhesion protein-1 having oxidase activity | |
| WO1999063094A3 (en) | Nucleotide and protein sequences of gpr1 and methods based thereon | |
| WO2000044898A3 (en) | Novel agouti and agouti-related peptide analogs | |
| DK1402270T3 (en) | Identification of modulators of xanthanuric acid neurotransmitter activity | |
| WO2004042363A3 (en) | In vivo imaging of e2f-regulated bioluminescent proteins | |
| WO2001067097A3 (en) | Method of identifying modulators of presenilin | |
| FI20000394A0 (en) | Substances related to or derived from GFRa4 and their use | |
| WO2002058323A3 (en) | Method for identifying modulators of bace | |
| ATE391915T1 (en) | USE OF GRF-1 PROTEIN TO SELECT MOLECULES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |